Rosiglitazone in Treating Patients With Liposarcoma

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically proven liposarcoma that is incurable with standard multimodality approaches (e.g., surgery and/or radiotherapy and/or chemotherapy)
• •* Well differentiated OR
• •* Dedifferentiated OR
• •* Myxoid/round cell OR
• •* Pleomorphic
• •Measurable disease
• •No clinically unstable brain metastases
• •No progression on prior troglitazone therapy for liposarcoma
• •PATIENT CHARACTERISTICS:
• •Age:
• •18 and over
• •Performance status:
• •ECOG 0-2
• •Life expectancy:
• •At least 3 months
• •Hematopoietic:
• •Absolute neutrophil count at least 1,000/mm3
• •Platelet count at least 90,000/mm3
• •Hepatic:
• •Bilirubin no greater than 2.0 mg/dL
• •SGOT less than 5 times upper limit of normal
• •Renal:
• •Creatinine no greater than 2.4 mg/dL
• •Cardiovascular:
• •No poorly controlled atrial arrhythmias, symptomatic angina pectoris, or myocardial infarction within the past 4 months
• •No symptomatic congestive heart failure, percutaneous transluminal coronary angioplasty, or coronary artery bypass graft within the past 3 months
• •Other:
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective barrier contraception
• •* Oral contraceptives are not considered effective contraception
• •No active retroviral disease
• •No condition that would preclude informed consent
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •Not specified
• •Chemotherapy:
• •See Disease Characteristics
• •Prior chemotherapy allowed and recovered
• •No concurrent cytotoxic therapy
• •Endocrine therapy:
• •No concurrent hormonal therapy
• •Radiotherapy:
• •See Disease Characteristics
• •Prior radiotherapy allowed and recovered
• •At least 6 months since prior radiotherapy to the sole site of measurable disease
• •Concurrent localized radiotherapy to a single site of disease allowed if there are other sites of measurable disease
• •Surgery:
• •Not specified